Multistimulation Group Therapy for Alzheimer's Disease

Multistimulation Group Therapy in Mild to Moderate Alzheimer's Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01893398

Enrollment

Registered

2013-07-09

Start date

2010-01-31

Completion date

Unknown

Last updated

2013-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

Our previous findings support the notion that group activity program, based on cognitive stimulation, recreational-occupational activities and physical-psychomotor exercises, can lead to an improvement in behavioral aspects for people with Alzheimer's Disease (AD). The purpose of this study is to clarify the efficacy of a rehabilitation program in outpatients affected by AD in mild to moderate stages.

Interventions

OTHERMultidimensional stimulation group therapy

The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

65 Years to 85 Years

Healthy volunteers

Inclusion criteria

* diagnosis of possible/probable AD * mild to moderate stage of AD (MMSE score of 15 - 24)and CDR score of 1-2 * range years in age (65-85) and in school attendance (5-17) * right handed

Exclusion criteria

* severe aphasia (Token test score \< 20) * severe auditory and/or visual loss * overt severe behavioral disturbances (delusions, hallucinations, agitation) * recent (three month before the MST) introduction or dose modification of the following pharmacological treatments: cholinesterase inhibitor, memantine, antidepressant or antipsychotic drugs.

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in behavioral level	Baseline, 10ws, 22ws	Neuropsychiatric Inventory scale
Change from baseline in cognitive level	Baseline, 10ws, 22 ws	ADAS cog scale
Change from baseline in quality of life	baseline, 10ws,22 ws	SF36 questionaire

Other

Measure	Time frame	Description
Functional MRI	baseline, 10 ws	Change from baseline in brain functioning. We used fMRI with cognitive task to detect possible changes (10 ws versus baseline) in brain activation patterns in PWA as a surrogate biomarker of efficacy.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026